Michael Gladstone - Jun 17, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Ommer Chohan, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Jun 17, 2022
Transactions value $
$11,500,005
Form type
4
Date filed
6/22/2022, 04:47 PM
Previous filing
May 26, 2021
Next filing
Jun 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Purchase $11.5M +767K $15.00 767K Jun 17, 2022 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney